Samsung Bioepis, a joint venture between the South Korean conglomerate and Biogen, is planning a jump to the Nasdaq with eyes on raising cash to market cheaper copies of blockbuster biologics.

…read more

Source: Samsung and Biogen plot an IPO for their biosimilars JV